10/17/2025
There are two exciting updates for metastatic colorectal cancer patients related to FRUZAQLA® (fruquintinib).
As of 10/1/25, FRUZAQLA® (fruquintinib) is covered at Cigna Healthcare*+.
Additionally, as of 7/1/25, FRUZAQLA® (fruquintinib) has been covered on CVS Caremark National Template Formularies.
These updates mean that most commercial patients will have more rapid access to FRUZAQLA and a lower co-pay.
This also means that ~95% of commercial lives are now covered for FRUZAQLA.
The hope is that these formulary updates help improve patient access and time to treatment start for FRUZAQLA.
For patients with commercial insurance who are concerned about out-of-pocket costs, the Takeda Oncology Co-Pay Assistance Program may be able to help reduce the out-of-pocket costs associated with FRUZAQLA. Terms and Conditions Apply.
For more information, visit https://www.takedaoncologycopay.com/